Johnson & Johnson Family of Companies
1 Johnson & Johnson Plaza
New Brunswick
New Jersey
08933
United States
Tel: 732-524-0400
Fax: 732-524-3300
Website: http://www.jnj.com/
2302 articles with Johnson & Johnson Family of Companies
-
The company posted an interim analysis of its Phase I/IIa trial that showed a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants and was well-tolerated.
-
Clinical Catch-Up: September 21-25
9/28/2020
The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look. -
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate
9/23/2020
First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssen's COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S
-
The J&J vaccine appears to require only a single dose. Several of the other candidate vaccines require two doses about 28 days apart.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 23, 2020.
-
Johnson & Johnson has become the next big pharma player to be accused in New York State's Department of Financial Services opioid industry probe.
-
Call for Award Applicants: Johnson & Johnson Seeks Female Researchers Working in Science, Technology, Engineering, Math, Manufacturing and Design
9/14/2020
The Women in STEM2D Scholars Award honors female scholars with $150,000 grant and three years of mentorship
-
Biopharma Leaders Unite to Stand with Science
9/8/2020
Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 4, 2020.
-
Janssen Pharmaceutical of Johnson & Johnson made a strategic call to halt development of pimodivir, an antiviral treatment for influenza A.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 21, 2020.
-
Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen's Leadership in Novel Treatments for Autoimmune Diseases
8/19/2020
Lead Asset Nipocalimab Provides Opportunity for Janssen to Deliver Transformative Treatments in Autoantibody-Driven Autoimmune Diseases
-
GI Windows Raises $16.4M in Series A-1 Financing
8/19/2020
GI Windows Medical Corp, a clinical-stage, privately-held medical device company, announced a $16.4 million Series A-1 financing.
-
Momenta Enters Definitive Agreement with Johnson & Johnson
8/19/2020
Johnson & Johnson to acquire Momenta for $52.50 per share in cash, representing a total equity value of $6.5 billion and a 70% premium to Momenta’s closing price on August 18, 2020
-
J&J said the acquisition will allow its subsidiary, Janssen Pharmaceutical, to broaden its leadership in immune-mediated diseases and drive further growth through expansion into autoantibody-driven disease.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 12, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 5, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 31, 2020.
-
Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies
7/30/2020
Study published in Nature shows J&J's investigational SARS-CoV-2 vaccine elicits a strong immune response that protects against subsequent infection
-
This morning Johnson & Johnson announced preclinical data that showed its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19.